Current Atherosclerosis Reports

, Volume 5, Issue 1, pp 67–72

Pharmacoeconomics of lipid-lowering drugs

  • Dean G. Smith
Article

DOI: 10.1007/s11883-003-0070-6

Cite this article as:
Smith, D.G. Curr Atheroscler Rep (2003) 5: 67. doi:10.1007/s11883-003-0070-6

Abstract

The widespread use and high cost of lipid-lowing drugs have resulted in numerous investigations of their cost effectiveness. Pharmacoeconomic analyses have considered initiation of treatment, maintenance therapy, and long-term outcomes of lipid-lowering therapy. Analyses have yielded a number of consistent messages, but the story continues to evolve as new trials, models, and drugs are introduced. Certain medications are more efficacious and associated with more cost-effective lipid-lowering therapy initiation. Other medications are lower priced and may be more cost effective for maintenance, contingent upon having achieved lipid-lowering goals. Finally, some medications have proven long-term cost effectiveness in trials and comparative cost effectiveness in models. Research is certain to further our understanding of the costs of lipid-lowering therapy and the methods needed to optimize expenditures.

Copyright information

© Current Science Inc. 2003

Authors and Affiliations

  • Dean G. Smith
    • 1
  1. 1.Department of Health Management & PolicyUniversity of MichiganAnn ArborUSA